Dr Lal Pathlabs Ltd

Dr Lal Pathlabs Ltd

₹ 2,924 -0.75%
24 Dec - close price
About

Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates. [1]

Key Points

About[1]
It is the largest diagnostics chain with a PAN India presence The company has 70+ yrs of experience in the field of diagnostics. The company has serviced 122 Mn+ patients
in the last 5 years.

  • Market Cap 24,537 Cr.
  • Current Price 2,924
  • High / Low 3,654 / 1,943
  • Stock P/E 56.3
  • Book Value 248
  • Dividend Yield 0.82 %
  • ROCE 27.1 %
  • ROE 21.4 %
  • Face Value 10.0

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 28.4%

Cons

  • Stock is trading at 11.8 times its book value
  • Promoter holding has decreased over last quarter: -0.68%
  • The company has delivered a poor sales growth of 11.0% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
470 422 416 440 467 429 431 480 532 476 479 534 584
337 323 311 331 337 325 315 344 369 346 349 379 399
Operating Profit 133 100 105 110 130 105 116 136 163 130 130 156 184
OPM % 28% 24% 25% 25% 28% 24% 27% 28% 31% 27% 27% 29% 32%
15 11 13 19 8 9 12 15 14 15 16 29 22
Interest 4 9 11 8 10 8 8 7 7 6 6 6 5
Depreciation 18 19 22 19 21 21 21 18 19 19 20 18 18
Profit before tax 126 83 85 102 106 84 98 125 151 120 120 161 183
Tax % 25% 26% 23% 22% 26% 26% 27% 25% 25% 26% 26% 24% 26%
94 62 65 80 79 63 71 94 113 88 90 123 135
EPS in Rs 11.27 7.40 7.83 9.56 9.43 7.51 8.56 11.22 13.54 10.58 10.72 14.72 16.18
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
421 541 637 765 882 1,024 1,165 1,274 1,491 1,879 1,769 1,967 2,073
334 406 486 562 651 768 882 946 1,083 1,366 1,308 1,408 1,473
Operating Profit 87 135 151 204 230 256 283 328 408 512 461 559 600
OPM % 21% 25% 24% 27% 26% 25% 24% 26% 27% 27% 26% 28% 29%
3 8 17 20 28 31 46 58 51 53 47 60 82
Interest 0 0 0 0 1 1 1 15 15 29 34 27 23
Depreciation 18 31 32 32 26 31 36 68 70 76 82 77 75
Profit before tax 71 111 135 192 231 256 292 303 374 461 391 516 584
Tax % 31% 34% 32% 34% 34% 34% 33% 26% 25% 25% 25% 26%
49 74 92 126 152 168 195 223 280 345 292 384 436
EPS in Rs 1,456.93 137.77 16.80 15.21 18.36 20.19 23.45 26.78 33.61 41.42 35.07 46.04 52.20
Dividend Payout % 11% 8% 9% 16% 16% 22% 26% 45% 60% 29% 17% 39%
Compounded Sales Growth
10 Years: 14%
5 Years: 11%
3 Years: 10%
TTM: 11%
Compounded Profit Growth
10 Years: 18%
5 Years: 14%
3 Years: 11%
TTM: 28%
Stock Price CAGR
10 Years: %
5 Years: 14%
3 Years: -6%
1 Year: 13%
Return on Equity
10 Years: 24%
5 Years: 22%
3 Years: 22%
Last Year: 21%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 3 54 55 83 83 83 83 83 83 83 83 83 84
Reserves 147 135 238 397 503 693 847 933 1,134 1,389 1,606 1,816 1,991
2 27 27 0 0 0 0 0 38 385 281 136 181
100 116 130 112 90 119 136 302 318 354 350 380 324
Total Liabilities 252 331 449 592 676 896 1,067 1,318 1,573 2,211 2,320 2,415 2,579
91 114 119 130 121 173 173 297 300 371 361 343 334
CWIP 1 0 1 4 17 9 3 11 9 14 5 6 1
Investments 80 20 49 74 134 174 214 253 171 1,062 1,213 1,143 1,274
80 197 280 384 404 540 677 757 1,093 764 740 924 969
Total Assets 252 331 449 592 676 896 1,067 1,318 1,573 2,211 2,320 2,415 2,579

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
79 96 94 142 167 189 208 272 373 426 428 478
-56 -86 -86 -148 -134 -166 -93 -19 -195 -449 -288 32
-15 -10 1 1 -32 13 -54 -187 -136 141 -270 -404
Net Cash Flow 9 0 9 -5 1 36 61 65 42 118 -131 106

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 17 16 17 17 17 14 17 14 16 13 13 14
Inventory Days 37 31 33 44 40 70 38 32 22 26
Days Payable 89 88 97 104 110 143 132 101 131 156
Cash Conversion Cycle 17 16 -35 -41 -47 -45 -54 -59 -79 -55 -96 -116
Working Capital Days -38 -28 -10 28 15 18 1 -16 -16 -15 -21 -22
ROCE % 54% 61% 51% 48% 44% 38% 34% 33% 34% 31% 22% 27%

Shareholding Pattern

Numbers in percentages

24 Recently
Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
55.23% 55.23% 55.05% 55.04% 55.04% 55.03% 55.01% 54.61% 54.60% 54.60% 54.60% 53.92%
25.45% 23.44% 22.37% 23.26% 25.80% 24.89% 23.27% 24.35% 25.36% 26.15% 25.43% 26.82%
6.57% 6.83% 6.52% 6.27% 6.20% 6.56% 8.34% 8.85% 9.27% 9.40% 12.42% 12.60%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.29% 0.29% 0.29% 0.29% 0.29% 0.29%
12.01% 13.80% 15.46% 14.84% 12.38% 13.01% 12.65% 11.48% 10.12% 9.24% 6.95% 6.02%
0.74% 0.70% 0.60% 0.58% 0.56% 0.51% 0.44% 0.41% 0.37% 0.32% 0.30% 0.33%
No. of Shareholders 1,35,0681,71,8461,84,5081,71,6021,79,6361,80,1631,74,4441,60,6791,49,9011,46,7411,31,1891,16,606

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls